Eisai brings new data and a clearer playbook for treating early Alzheimer’s to neurology’s biggest stage as it enters real-world care.
Every new drug eventually leaves the controlled world of clinical trials and enters the unpredictability of everyday care. That’s where lecanemab finds itself now.
At the 2026 American Academy of Neurology (AAN) Annual Meeting in Chicago, US-based pharma company Eisai, a subsidiary of Tokyo-based Eisai Co Ltd, specializing in neurology and oncology research, development and manufacturing, is presenting a broad sweep of new data on its Alzheimer’s therapy – 14 studies in total, including oral sessions and posters [1]. This time, it’s less spotlight on whether the drug works and more attention on how it works when the variables aren’t neatly controlled. In other words: real people, real clinics, real constraints.
Lecanemab is designed to target amyloid-beta, sticky protein fragments that accumulate in the brain and are widely linked to Alzheimer’s disease. For many years, science has focused on clearing these plaques, almost like unclogging pipes in a system under pressure. However, clearing the blockage is only part of the story. What Eisai is now trying to show is what happens after.
New findings, including data from the ongoing Clarity AD extension study, track patients over longer periods, up to 48 months. The question isn’t just whether decline slows, but whether that slowing holds over time. Some analyses go a step further, estimating “time saved” – how much longer a person might maintain their cognitive abilities compared to expected decline.
It’s not a perfect measure. Alzheimer’s doesn’t move in straight lines, but framing outcomes in terms of time means more human-centered metrics.
How the drug is given is also a practical evolution underway. Eisai is presenting data on a subcutaneous formulation of lecanemab, an under-the-skin injection that could complement or eventually replace intravenous infusions. It’s the difference between hospital-bound treatment and something closer to routine care. A therapy that works but is difficult to administer risks becoming a solution in theory rather than in practice.
One of the more compelling ideas emerging from Eisai’s AAN presence is the concept of “smoldering” Alzheimer’s disease. The premise is unsettling but increasingly accepted. The disease begins long before symptoms appear, quietly altering the brain over decades. By the time memory loss becomes noticeable, much of the damage may already be done.
Eisai’s symposium at AAN leans into this idea, exploring how earlier detection and intervention could change the disease’s trajectory. This includes improving how clinicians interpret biomarkers, those subtle biological signals that hint at what’s happening beneath the surface.
Building a playbook for early care
If Alzheimer’s is going to be treated earlier, clinicians need a clearer roadmap. Right now, that roadmap is still being drawn.
Several of Eisai’s presentations focus exactly on how to standardize the process of identifying and treating early Alzheimer’s. From consensus recommendations among neurologists to studies examining how patients first present in clinics, the goal is to reduce uncertainty. Who should be eligible for treatment? When is the right moment to start? How should risks and benefits be communicated?
Real-world data, drawn from registries and geriatric practices, is beginning to fill in those gaps. It captures what clinical trials can’t fully simulate: variation among patients, differences across healthcare settings and the everyday decisions clinicians make as guidelines are still evolving.
All of this feeds into a larger, often unspoken tension in longevity science. We are getting better at extending life, but extending cognitive health – that’s proving harder. Alzheimer’s sits right at that fault line. It’s the condition that can turn added years into something more fragile, more dependent, more uncertain.
What Eisai is presenting at AAN doesn’t resolve that tension, but it does suggest a path forward where treatment begins earlier, care is more standardized and therapies are shaped as much by real-world use as by clinical promise.
There’s still a long way to go. Real-world evidence is messy by nature, and early optimism has, in the past, outpaced long-term outcomes in Alzheimer’s research. Something is changing in tone, though. The field is starting to act upstream, rather than waiting for late-stage disease to declare itself.
